Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations

COVID-19 has proven to be particularly serious and life-threatening for patients presenting with pre-existing pathologies. Patients affected by rheumatic musculoskeletal disease (RMD) are likely to have impaired immune responses against SARS-CoV-2 infection due to their compromised immune system and...

Descripción completa

Detalles Bibliográficos
Autores principales: Favalli, Andrea, Favalli, Ennio Giulio, Gobbini, Andrea, Zagato, Elena, Bombaci, Mauro, Maioli, Gabriella, Pesce, Elisa, Donnici, Lorena, Gruarin, Paola, Biggioggero, Martina, Curti, Serena, Manganaro, Lara, Marchisio, Edoardo, Bevilacqua, Valeria, Martinovic, Martina, Fabbris, Tanya, Sarnicola, Maria Lucia, Crosti, Mariacristina, Marongiu, Laura, Granucci, Francesca, Notarbartolo, Samuele, Bandera, Alessandra, Gori, Andrea, De Francesco, Raffaele, Abrignani, Sergio, Caporali, Roberto, Grifantini, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226581/
https://www.ncbi.nlm.nih.gov/pubmed/35757699
http://dx.doi.org/10.3389/fimmu.2022.873195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226581/
https://www.ncbi.nlm.nih.gov/pubmed/35757699
http://dx.doi.org/10.3389/fimmu.2022.873195

Ejemplares similares